Quality defects: EMA updates Defective Product Report Template

Recommendation
18-20 November 2025
Heidelberg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
Marketing and manufacturing authorization holders should report a quality defect of a centrally authorized medicine, including suspected defects, to EMA following the instructions provided.
The EMA's ("European Medicines Agency") "Defective product report template", which is supposed to be used for notifications of drug product quality defects to the EMA, has recently been updated. Inter alia, the document has been aligned with the terminology of the "Medical Dictionary for Regulatory Activities (MedDRA)". Furthermore, the template is now designed in a more user-friendly manner. Also, detailed instructions on how to use the template (How to use the defective product report to notify a quality defect to European Medicines Agency) have been published and the notes on how to report quality defects to the EMA have been updated. The aforementioned documents can be found on the EMA website under Quality defects and recalls - "Reporting a quality defect to EMA".
The aim is to harmonize the process of reporting and investigating product quality defects of centrally authorized medicinal products. The EMA also encourages national competent authorities to use this template in their national reporting.
Related GMP News
17.09.2025When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
17.09.2025Dealing with Systems without Audit Trail Functionality
17.09.2025Why is RCA (Root Cause Analysis) so important?
10.09.2025The Use of Hoses in Pharmaceutical Production
10.09.2025Revision of EU-GMP Chapter 1 planned with Consultation Phase
10.09.2025Audit Trail Review by the QP / Dealing with a Lack of Justification